First-Line Nivolumab plus Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743

被引：0

作者：

Baas, P. ^{[1
,2
]}

Scherpereel, A. ^{[3
]}

Nowak, A. ^{[4
]}

Fujimoto, N. ^{[5
]}

Peters, S. ^{[6
]}

Tsao, A. ^{[7
]}

Mansfield, A. ^{[8
]}

Popat, S. ^{[9
]}

Jahan, T. ^{[10
]}

Antonia, S. ^{[11
]}

Oulkhouir, Y. ^{[12
]}

Bautista, Y. ^{[13
]}

Cornelissen, R. ^{[14
]}

Greillier, L. ^{[15
]}

Grossi, F. ^{[16
]}

Kowalski, D. M. ^{[17
]}

Rodriguez-Cid, J. ^{[18
]}

Aanur, P. ^{[19
]}

Baudelet, C. ^{[19
]}

Zalcman, G. ^{[20
]}

机构：

[1] Netherlands Canc Inst, Amsterdam, Netherlands

[2] Leiden Univ, Amsterdam, Netherlands

[3] Univ Lille, CHU Lille, INSERM U1189, Pulm & Thorac Oncol,OncoThAI, Lille, France

[4] Univ Western Australia, Perth, WA, Australia

[5] Okayama Rosai Hosp, Okayama, Japan

[6] Lausanne Univ Hosp, Lausanne, Switzerland

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Mayo Clin, Rochester, MN USA

[9] Royal Marsden Hosp, London, England

[10] USCF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] CHU Caen, Hop Cote De Nacre, Caen, France

[13] Ctr Med Nacl Siglo XXI, Mexico City, DF, Mexico

[14] Erasmus MC Canc Inst, Rotterdam, Netherlands

[15] Aix Marseille Univ, Marseille, France

[16] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[17] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[18] Ctr Oncol Med Sur, Mexico City, DF, Mexico

[19] Bristol Myers Squibb Co, Princeton, NJ USA

[20] Univ Paris Diderot, Paris, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2020年 / 15卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2908

引用

页码：E42 / E42

页数：1

共 50 条

[21] Efficacy of First-Line Nivolumab Plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM)
Enrico, Diego
Gomez, Juan Elias
Aguirre, Danilo
Tissera, Natalia Soledad
Tsou, Florencia
Pupareli, Carmen
Tanco, Delfina Peralta
Waisberg, Federico
Rodriguez, Andres
Rizzo, Manglio
Minatta, Nicolas
Rafael, Picon
Basbus, Luis
Lupinacci, Lorena
Kaen, Diego
Ramos, Mauro
Bluthgen, Virginia
Castagneris, Nicolas
Coppola, Maria Pia
Scocimarro, Alejandra
Guerra, Maria Florencia
Perfetti, Aldo
Levit, Patricio
Galvez-Nino, Marco
Mas, Luis
Rojas, Leonardo
Zuluaga, Jairo
Chacon, Matias
Corrales, Luis
Samtani, Suraj
Arrieta, Oscar
Cardona, Andres
Remon, Jordi
Martin, Claudio
CLINICAL LUNG CANCER, 2024, 25 (08)
[22] FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma COMMENT
Zauderer, Marjorie G.
ONCOLOGY-NEW YORK, 2020, 34 (11): : 503 - 503
[23] First-Line Nivolumab Plus Ipilimumab versus Chemotherapy in NSCLC
不详
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : 465 - 465
[24] A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol
Fujimoto, Nobukazu
Aoe, Keisuke
Kozuki, Toshiyuki
Oze, Isao
Kato, Katsuya
Kishimoto, Takumi
Hotta, Katsuyuki
CLINICAL LUNG CANCER, 2018, 19 (05) : E705 - E707
[25] Safety of First-Line Nivolumab Plus Ipilimumab in Very Old (≥ 80 Years) Patients With Unresectable Malignant Pleural Mesothelioma: A Retrospective Single-Center Case Series
Shimamoto, Takayuki
Morimoto, Yoshie
Nitta, Naohiro
Yoshida, Rie
Tani, Nozomi
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (01)
[26] CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma
Uprety, Dipesh
CLINICAL LUNG CANCER, 2021, 22 (02) : 71 - 73
[27] A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: JME-001
Fujimoto, N.
Kozuki, T.
Aoe, K.
Miyamoto, Y.
Wada, S.
Harada, D.
Yoshida, M.
Sakurai, J.
Hotta, K.
ANNALS OF ONCOLOGY, 2020, 31 : S1077 - S1077
[28] JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
Miyamoto, Yosuke
Kozuki, Toshiyuki
Aoe, Keisuke
Wada, Sae
Harada, Daijiro
Yoshida, Michihiro
Sakurai, Jun
Hotta, Katsuyuki
Fujimoto, Nobukazu
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
[29] First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC : The Updated Outcomes From CheckMate 9LA
Zhao, Binghao
Ma, Wenbin
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (09) : E101 - E102
[30] Liposomal doxorubicin and cisplatin as first-line chemotherapy in unresectable malignant pleural mesothelioma: A phase II study
Arrieta, O., Sr.
Medina, L. A., Sr.
Guzman, E.
Rios Trejo, M. A., Sr.
Mendoza, D.
Atorga Ramos, A.
Martinez Barrera, L.
Hernandez Pedro, N.
Arechaga Ocampo, E.
De la Garza, J.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

← 1 2 3 4 5 →